Abbott Laboratories (NYSE: ABT) reported its financial results for the quarter ended March 31, 2020 today.
The company reported a 16% drop in earnings for the first quarter of 2020 due to tax expense despite a 2.5% increase in the top-line. Abbott is suspending its previously announced annual guidance for 2020 due to uncertainties regarding the duration and impact of the coronavirus (COVID-19) pandemic.
Abbott launched three critical new tests for COVID-19, two molecular tests and one serology blood test for the detection of the antibody. While molecular testing detects whether someone has the virus, antibody tests determine if someone was previously infected.
The business world is still struggling to come out of the virus-induced slowdown, but it seems almost every retail segment benefited from the pandemic at some point. The vaccination drive
General Mills (GIS): Three factors that are expected to help drive growth for the food company going forward
Shares of General Mills Inc. (NYSE: GIS) were up 3.2% on Wednesday after the company delivered better-than-expected results for the first quarter of 2022. Net sales rose 4% year-over-year to
It is estimated that the alternative investments industry has expanded at a compound annual rate of 10.2% over the past ten years and had $11 trillion in assets under management